<DOC>
	<DOCNO>NCT01004939</DOCNO>
	<brief_summary>The objective retrospective study gather information fondaparinux use pre- , peri- and/or postpartum prophylaxis treatment venous thromboembolism ( VTE ) order fill information gap concern off-label use fondaparinux pregnancy .</brief_summary>
	<brief_title>Retrospective Study Patients Who Were Treated With Fondaparinux Pre- , Peri- and/or Postpartum Prophylaxis Treatment Venous Thromboembolism</brief_title>
	<detailed_description>During pregnancy generally enhance risk develop venous thromboembolism ( VTE ) . Although event rare may lead serious risk mothers´ children´s health . Compared non-pregnant woman , pregnant woman five-fold risk develop VTE . Due characteristic spectrum side effect generally long duration exposure pregnancy prefer anticoagulant may produce potentially dangerous side effect , bleeding , heparin-induced thrombocytopenia ( HIT ) , allergic reaction , osteoporosis , congenital anomaly . Today , low-molecular weight heparin ( LMWH ) prefer agent anticoagulation pregnancy . Compared unfractioned heparin ( UFH ) LMWHs advantage low bleeding risk , low rate allergic reaction HIT , predictable response longer half-life make dose convenient ( od bid ) . Still , considerable proportion pregnancy heparin intolerance ( allergic reaction HIT ) make inevitable change another anticoagulant . On one hand , fondaparinux repeatedly report successful VTE prophylaxis pregnancy allergic reaction heparin , heparinoids , occur . Additionally , considerable amount oral report reach GSK additional number successful case past . On hand , systematic overall view many pregnancy already treat reason , successful . Due increase certain risk factor , obesity grow age mother childbirth associate need anticoagulation , expect increase number case alternative anticoagulation heparin may need . There number potential advantage fondaparinux heparin , daily application , dose adjustment need body weight monitoring thrombocyte , low potential causing intolerance reaction risk HIT . The objective retrospective study gather information fondaparinux use pre- , peri- and/or postpartum prophylaxis treatment VTE order fill information gap concern off-label use fondaparinux pregnancy .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients treat fondaparinux pre , peri and/or postpartum 7 day VTE prophylaxis treatment , especially history abortion , and/or stillbirth , VTE , severe fetal maternal complication pregnancy , severe inherit acquire thrombophilias , longterm anticoagulation ( e. g. patient mechanical heart valve ) and/or intolerance heparin heparinoids heparininduced thrombocytopenia ( HIT ) Patients treat fondaparinux less 7 day Patient treat fondaparinux postpartum</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>prophylaxis</keyword>
	<keyword>venous thromboembolism</keyword>
	<keyword>postpartum</keyword>
	<keyword>fondaparinux</keyword>
	<keyword>pregnancy</keyword>
</DOC>